Kwatra, Shawn G; Yosipovitch, Gil; Legat, Franz J; Reich, Adam; Paul, Carle; Simon, Dagmar; Naldi, Luigi; Lynde, Charles; De Bruin-Weller, Marjolein S; Nahm, Walter K; Sauder, Maxwell; Gharib, Rola; Barbarot, Sebastien; Szepietowski, Jacek C; Conrad, Curdin; Fleischer, Alan; Laquer, Vivian T; Misery, Laurent; Serra-Baldrich, Esther; Lapeere, Hilde; ... (2023). Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. The New England journal of medicine, 389(17), pp. 1579-1589. Massachusetts Medical Society 10.1056/NEJMoa2301333
Text
nejmoa2301333.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (526kB) |
BACKGROUND
Prurigo nodularis is a chronic, debilitating, and severely pruritic neuroimmunologic skin disease. Nemolizumab, an interleukin-31 receptor alpha antagonist, down-regulates key pathways in the pathogenesis of prurigo nodularis.
METHODS
In this phase 3, double-blind, multicenter, randomized trial, we assigned adults with moderate-to-severe prurigo nodularis to receive an initial 60-mg dose of nemolizumab followed by subcutaneous injections of 30 mg or 60 mg (depending on baseline weight) every 4 weeks for 16 weeks or matching placebo. The primary end points were an itch response (a reduction of ≥4 points on the Peak Pruritus Numerical Rating Scale [PP-NRS; scores range from 0 to 10, with higher scores indicating more severe itch]) and an Investigator's Global Assessment (IGA) response (a score of 0 [clear] or 1 [almost clear] on the IGA [scores range from 0 to 4] and a reduction from baseline to week 16 of ≥2 points). There were five key secondary end points.
RESULTS
A total of 274 patients underwent randomization; 183 were assigned to the nemolizumab group, and 91 to the placebo group. Treatment efficacy was shown with respect to both primary end points at week 16; a greater percentage of patients in the nemolizumab group than in the placebo group had an itch response (56.3% vs. 20.9%; strata-adjusted difference, 37.4 percentage points; 95% confidence interval [CI], 26.3 to 48.5), and a greater percentage in the nemolizumab group had an IGA response (37.7% vs. 11.0%; strata-adjusted difference, 28.5 percentage points; 95% CI, 18.8 to 38.2) (P<0.001 for both comparisons). Benefits were observed for the five key secondary end points: itch response at week 4 (41.0% vs. 7.7%), PP-NRS score of less than 2 at week 4 (19.7% vs. 2.2%) and week 16 (35.0% vs. 7.7%), and an improvement of 4 or more points on the sleep disturbance numerical rating scale (range, 0 [no sleep loss] to 10 [unable to sleep at all]) at week 4 (37.2% vs. 9.9%) and week 16 (51.9% vs. 20.9%) (P<0.001 for all comparisons). The most common individual adverse events were headache (6.6% vs. 4.4%) and atopic dermatitis (5.5% vs. 0%).
CONCLUSIONS
Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT04501679; EudraCT number, 2019-004789-17.).
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology |
UniBE Contributor: |
Simon, Dagmar |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1533-4406 |
Publisher: |
Massachusetts Medical Society |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
30 Oct 2023 12:12 |
Last Modified: |
31 Oct 2023 13:30 |
Publisher DOI: |
10.1056/NEJMoa2301333 |
PubMed ID: |
37888917 |
BORIS DOI: |
10.48350/188253 |
URI: |
https://boris.unibe.ch/id/eprint/188253 |